News

ADAG
Adagene Inc. News

This news view pulls recent coverage and headlines tied to ADAG.

Latest Close

$2.00

1y Change

$0.20 (+11.11%)

Market Cap

$134,286,688.00

Sector

Healthcare

Industry

Biotechnology

Recommendation

none

Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

GlobeNewswire • Nov 9, 2026

Read article

What Does Incyte (INCY) First Patient Dosing Mean For Its Colorectal Cancer Pipeline?

Simply Wall St. • Oct 31, 2026

Read article

Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer

GlobeNewswire • Oct 28, 2026

Read article

Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

GlobeNewswire • Oct 27, 2026

Read article

Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer

MarketBeat • Oct 25, 2026

Read article

Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts

MarketBeat • Oct 16, 2026

Read article